Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity.
Compte M, Harwood SL, Erce-Llamazares A, Tapia-Galisteo A, Romero E, Ferrer I, Garrido-Martin EM, Enguita AB, Ochoa MC, Blanco B, Oteo M, Merino N, Nehme-Álvarez D, Hangiu O, Domínguez-Alonso C, Zonca M, Ramírez-Fernández A, Blanco FJ, Morcillo MA, Muñoz IG, Melero I, Rodriguez-Peralto JL, Paz-Ares L, Sanz L, Alvarez-Vallina L. Compte M, et al. Among authors: harwood sl. Clin Cancer Res. 2021 Jun 1;27(11):3167-3177. doi: 10.1158/1078-0432.CCR-20-4625. Epub 2021 Mar 30. Clin Cancer Res. 2021. PMID: 33785484
The coming of age of engineered multivalent antibodies.
Nuñez-Prado N, Compte M, Harwood S, Álvarez-Méndez A, Lykkemark S, Sanz L, Álvarez-Vallina L. Nuñez-Prado N, et al. Drug Discov Today. 2015 May;20(5):588-94. doi: 10.1016/j.drudis.2015.02.013. Epub 2015 Mar 7. Drug Discov Today. 2015. PMID: 25757598 Review.
Bispecific light T-cell engagers for gene-based immunotherapy of epidermal growth factor receptor (EGFR)-positive malignancies.
Mølgaard K, Harwood SL, Compte M, Merino N, Bonet J, Alvarez-Cienfuegos A, Mikkelsen K, Nuñez-Prado N, Alvarez-Mendez A, Sanz L, Blanco FJ, Alvarez-Vallina L. Mølgaard K, et al. Among authors: harwood sl. Cancer Immunol Immunother. 2018 Aug;67(8):1251-1260. doi: 10.1007/s00262-018-2181-5. Epub 2018 Jun 4. Cancer Immunol Immunother. 2018. PMID: 29869168 Free PMC article.
Case Report: An EGFR-Targeted 4-1BB-agonistic Trimerbody Does Not Induce Hepatotoxicity in Transgenic Mice With Liver Expression of Human EGFR.
Compte M, Harwood SL, Martínez-Torrecuadrada J, Perez-Chacon G, González-García P, Tapia-Galisteo A, Van Bergen En Henegouwen PMP, Sánchez A, Fabregat I, Sanz L, Zapata JM, Alvarez-Vallina L. Compte M, et al. Among authors: harwood sl. Front Immunol. 2021 Jan 7;11:614363. doi: 10.3389/fimmu.2020.614363. eCollection 2020. Front Immunol. 2021. PMID: 33488625 Free PMC article.
Tumor targeted 4-1BB agonist antibody-albumin fusions with high affinity to FcRn induce anti-tumor immunity without toxicity.
Hangiu O, Compte M, Dinesen A, Navarro R, Tapia-Galisteo A, Mandrup OA, Erce-Llamazares A, Lázaro-Gorines R, Nehme-Álvarez D, Domínguez-Alonso C, Harwood SL, Alfonso C, Blanco B, Rubio-Pérez L, Jiménez-Reinoso A, Díez-Alonso L, Blanco FJ, Sanz L, Howard KA, Álvarez-Vallina L. Hangiu O, et al. Among authors: harwood sl. iScience. 2022 Aug 17;25(9):104958. doi: 10.1016/j.isci.2022.104958. eCollection 2022 Sep 16. iScience. 2022. PMID: 36072551 Free PMC article.
Dendritic Cell-Mediated Cross-Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS-CoV-2.
Lázaro-Gorines R, Pérez P, Heras-Murillo I, Adán-Barrientos I, Albericio G, Astorgano D, Flores S, Luczkowiak J, Labiod N, Harwood SL, Segura-Tudela A, Rubio-Pérez L, Nugraha Y, Shang X, Li Y, Alfonso C, Adipietro KA, Abeyawardhane DL, Navarro R, Compte M, Yu W, MacKerell AD Jr, Sanz L, Weber DJ, Blanco FJ, Esteban M, Pozharski E, Godoy-Ruiz R, Muñoz IG, Delgado R, Sancho D, García-Arriaza J, Álvarez-Vallina L. Lázaro-Gorines R, et al. Among authors: harwood sl. Adv Sci (Weinh). 2023 Dec;10(34):e2304818. doi: 10.1002/advs.202304818. Epub 2023 Oct 20. Adv Sci (Weinh). 2023. PMID: 37863812 Free PMC article.
A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response.
Rubio-Pérez L, Lázaro-Gorines R, Harwood SL, Compte M, Navarro R, Tapia-Galisteo A, Bonet J, Blanco B, Lykkemark S, Ramírez-Fernández Á, Ferreras-Gutiérrez M, Domínguez-Alonso C, Díez-Alonso L, Segura-Tudela A, Hangiu O, Erce-Llamazares A, Blanco FJ, Santos C, Rodríguez-Peralto JL, Sanz L, Álvarez-Vallina L. Rubio-Pérez L, et al. Among authors: harwood sl. Oncoimmunology. 2023 Apr 24;12(1):2205336. doi: 10.1080/2162402X.2023.2205336. eCollection 2023. Oncoimmunology. 2023. PMID: 37114242 Free PMC article.
28 results